Myriad Genetics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 61.3 million compared to USD 35.1 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 0.43 a year ago. Diluted loss per share from continuing operations was USD 0.75 compared to USD 0.43 a year ago.
For the nine months, net loss was USD 232.1 million compared to USD 69.7 million a year ago. Basic loss per share from continuing operations was USD 2.84 compared to USD 0.87 a year ago. Diluted loss per share from continuing operations was USD 2.84 compared to USD 0.87 a year ago.